Dicerna Pharmaceuticals, which is developing RNAi therapeutics for the treatment of rare liver disease and cancer, raised the proposed deal size for its upcoming IPO on Tuesday. The Watertown, MA-based company now plans to raise $84 million by offering 6.0 million shares at $14 per share. The company had previously filed to offer 5.0 million shares at a range of $11 to $13. At the midpoint of the revised range, Dicerna Pharmaceuticals would raise 40% greater proceeds than previously anticipated.
Dicerna Pharmaceuticals, which was founded in 2006 and booked $6 million in collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol DRNA. The company initially filed confidentially on November 8, 2013. Jefferies, Leerink Partners and Stifel are the joint bookrunners on the deal. It is expected to price during the week of January 27, 2014.
